AFM13
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Peripheral T Cell Lymphoma
Conditions
Peripheral T Cell Lymphoma, Transformed Mycosis Fungoides
Trial Timeline
Nov 13, 2019 → Jan 11, 2024
NCT ID
NCT04101331About AFM13
AFM13 is a phase 2 stage product being developed by Affimed for Peripheral T Cell Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT04101331. Target conditions include Peripheral T Cell Lymphoma, Transformed Mycosis Fungoides.
What happened to similar drugs?
8 of 20 similar drugs in Peripheral T Cell Lymphoma were approved
Approved (8) Terminated (2) Active (11)
Hype Score Breakdown
Clinical
12
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04101331 | Phase 2 | Completed |
| NCT02321592 | Phase 2 | Completed |
Competing Products
20 competing products in Peripheral T Cell Lymphoma